Allergy Therapeutics plc (AGY.L)
AGY.L Stock Price Chart
Explore Allergy Therapeutics plc interactive price chart. Choose custom timeframes to analyze AGY.L price movements and trends.
AGY.L Company Profile
Discover essential business fundamentals and corporate details for Allergy Therapeutics plc (AGY.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
11 Oct 2004
Employees
612.00
CEO
Manuel Llobet
Description
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
AGY.L Financial Timeline
Browse a chronological timeline of Allergy Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Mar 2026
Upcoming earnings on 4 Nov 2025
Earnings released on 31 Mar 2025
EPS came in at -£0.00, while revenue for the quarter reached £34.03M, meeting expectations.
Earnings released on 6 Nov 2024
EPS came in at -£0.01 falling short of the estimated -£0.01 by -25.77%, while revenue for the quarter reached £21.63M, meeting expectations.
Earnings released on 27 Mar 2024
EPS came in at -£0.01, while revenue for the quarter reached £33.57M, missing expectations by -0.08%.
Stock split effective on 28 Sept 2023
Shares were split 63:29, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Sept 2023
EPS came in at -£0.05 falling short of the estimated -£0.01 by -452.66%, while revenue for the quarter reached £19.69M, missing expectations by -73.75%.
Earnings released on 19 Jun 2023
EPS came in at -£0.01 falling short of the estimated -£0.00 by -179.57%, while revenue for the quarter reached £39.90M, beating expectations by 0.00%.
Earnings released on 29 Sept 2022
EPS came in at -£0.03 falling short of the estimated -£0.01 by -244.63%, while revenue for the quarter reached £24.07M, missing expectations by -62.91%.
Earnings released on 31 Dec 2021
EPS came in at £0.01, while revenue for the quarter reached £48.70M, missing expectations by -0.01%.
Earnings released on 30 Jun 2021
EPS came in at -£0.02, while revenue for the quarter reached £30.30M.
Earnings released on 31 Dec 2020
EPS came in at £0.02, while revenue for the quarter reached £54.03M, beating expectations by +0.06%.
Earnings released on 23 Sept 2020
EPS came in at -£0.01, while revenue for the quarter reached £27.73M.
AGY.L Stock Performance
Access detailed AGY.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.